{"name":"Sensei Biotherapeutics","slug":"sensei","ticker":"SNSE","exchange":"NASDAQ","domain":"senseibio.com","description":"Sensei Biotherapeutics is a clinical-stage biopharmaceutical company focused on the development of novel immunotherapies for the treatment of cancer. The company's pipeline includes several programs targeting various types of cancer, with a focus on immuno-oncology. Sensei Biotherapeutics has a strong presence in the immuno-oncology market and is working to bring innovative treatments to patients. The company's lead programs have shown promising results in clinical trials, positioning it for potential future growth.","hq":"Gaithersburg, MD","founded":0,"employees":"","ceo":"John Celebi","sector":"Immuno-Oncology","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"$45M","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":-30157000,"cash":45361000,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2030-06-01","label":"SB101 patent cliff ($0.00 at risk)","drug":"SB101","type":"patent_expiry","sentiment":"negative"},{"date":"2032-06-01","label":"SB102 patent cliff ($0.00 at risk)","drug":"SB102","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[{"date":"2024-02-22","type":"earnings","headline":"Sensei Biotherapeutics Reports Fourth Quarter and Full Year 2023 Financial Results","summary":"Sensei Biotherapeutics reported its financial results for the fourth quarter and full year 2023, highlighting progress in its clinical pipeline and strong cash position.","drugName":"","sentiment":"neutral"},{"date":"2023-12-18","type":"deal","headline":"Sensei Biotherapeutics Announces Collaboration with Merck KGaA to Develop Novel Immunotherapies","summary":"Sensei Biotherapeutics entered into a collaboration with Merck KGaA to develop novel immunotherapies for the treatment of cancer.","drugName":"","sentiment":"positive"}],"realNews":[{"date":"2026-03-30","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"date":"2026-03-30","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTFBRak10S3hXX29YZmc0UV9ERFNoUXozREVNUUxtUGI0MU5IZUh0b2ZNNm5DQ0liUHAyYzJTTzJjY0Z2VEdkVVE0aUM2RDFmOVMzLVFDU255UGtqaXFJZXB1M2dvLWhlb3dGZXJNaS1R?oc=5","date":"2026-03-22","type":"pipeline","source":"Stock Titan","summary":"If You Invested $1,000 in Sensei Biotherapeutics, Inc. (SNSE) - Stock Titan","headline":"If You Invested $1,000 in Sensei Biotherapeutics, Inc. (SNSE)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi1wFBVV95cUxPX05GNXYyaWpOTjlnNklFWnVqUkpFQ0c1SkNjUlJqQVpzakpCdlIyXzBldVA0ZEVZVDNtSENGRWJkWklSTTZfU2hIYUU5b2FZUXd1aHVUaXpyMjduZUc3bWNIT0JmYVRSUFhHR2xneFAxdl9EZ29UUm14TU9aQU9kal9CUEJCd05wemE2YUlYU20zUzZnSTRfZEJUclN0OXByNGd3dWYyOERVS2dEMWRMTGxjdnZyOEZlUl83dlpiQXozbGctMzhXaGd6eG0zSzY3RHZkS2ZmSQ?oc=5","date":"2026-02-25","type":"pipeline","source":"Business Wire","summary":"Sensei Biotherapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire","headline":"Sensei Biotherapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMigAJBVV95cUxQc1Z6cUlpTndzX1BmMndHelA1bGQ3aTRPWmh6NHhma1ZRM21IR1ZrSGlPd2RIRXkwUmlvNzRHQV9oRHpMTXYzNWE3TmtwMEFzMFRZTjN3cVNYV3lFVG9oMVJYeDc0VVZxQm9Bak9pWUxqQXBoMHFNX3pqdmt3NHdySk5LLUVXTm8tX1VzejBpdlFFVHJTYUxMenFxNkUydXp1N19DN1BXWGhsVk1GQTRYemNUZFJSSEhjb1RJcTdoUE1Sd1ZLRHZjazVKTFZ5N3FDc096ZF90cjRLSzNPUGlKbE9FVGJtMW84Tlh2cU1OM0wwR0xlQmJBeXBYbUxfd1NB?oc=5","date":"2026-02-18","type":"pipeline","source":"Business Wire","summary":"Sensei Biotherapeutics Announces Acquisition of Faeth Therapeutics and $200 Million Concurrent Private Placement - Business Wire","headline":"Sensei Biotherapeutics Announces Acquisition of Faeth Therapeutics and $200 Million Concurrent Private Placement","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipwFBVV95cUxOelF3Y2NGRjNfbUZVRVp0bUptOVhqN0xqZERsSks4cnlTUklTTkIyWERIbkJrQWl2NUF3SldwdTJwdjhUbkxGVzZqSVBFVVdjWHlENjRuazM1Rkp1NENzQVlILVFGTVJnX05HWUt4aHU3VEt6Q0ZwdUZtTkFNU0kxa2FJNXUyZjJTN19nYzM3X3pkUWtvc0wyQ3JYdnBkTjJOLS1IdWZrQQ?oc=5","date":"2026-02-18","type":"deal","source":"bioworld.com","summary":"Merger deal renews Faeth in Sensei; Piktor brightens, stock jumps - bioworld.com","headline":"Merger deal renews Faeth in Sensei; Piktor brightens, stock jumps","sentiment":"neutral"},{"date":"2026-02-18","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2026-02-13","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2025-12-23","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihgFBVV95cUxQYWh1SUtnMFFkMlBRQXlQcGlFRkYtakNFdDExRVYzSlNrM0ZTM21XZHRtU280c0lTeXZHR1JERDg0YkJxR0ZyUmZteEpVMXFJZkZDZnd1TUdnNUh1SE1HQ3Y1VzAydFdFU1VSdmdBZUVpYTR6Mlc3NGhGOUJBM1U0UjRsa1pkQQ?oc=5","date":"2025-11-17","type":"deal","source":"The Business Journals","summary":"Boston biotech cuts 65% of workforce as it explores sale or merger - The Business Journals","headline":"Boston biotech cuts 65% of workforce as it explores sale or merger","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiZkFVX3lxTE12LTlSa1FqNmR4bExfb0cwWXI2OGtES18xcmowU1RraVFwYTJHbzh2TWdYdGl5T2hYTklaQkxKY3pXVjRxYTJrSHdVWThNYUswMUlmZXR1S0dZRGgwRVd2dkVrLVV3Zw?oc=5","date":"2024-05-11","type":"pipeline","source":"MarketBeat","summary":"Sensei Biotherapeutics (SNSE) Stock Forecast and Price Target 2026 - MarketBeat","headline":"Sensei Biotherapeutics (SNSE) Stock Forecast and Price Target 2026","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivwFBVV95cUxPMVRuUTU1a3RIcHd0YVJ0WDJjQmxSa09GczBYLVlBcnhYQTAtNEVETHBvNFFiUGlkM2ViZ3BXNmZmZlU3OVpMWGRuOEFxZzA3NWpFMlk0cUhSQ3pKdWxfNFp1VUtMcDdzNUVMZTZocXBzNVhiUmhZb3ZfUE5LTjhtUU5UUXBIY1hqS0ZMQURmNkZPa3dPRmpia2psT3JfNmpSRl9kVXFhVm51S3FGQk1JZi01bU1aaWJwWkVRdXlhdw?oc=5","date":"2022-06-01","type":"pipeline","source":"citybiz","summary":"Sensei Biotherapeutics Appoints Patrick Gallagher, MBA, MPH, as Chief Business Officer - citybiz","headline":"Sensei Biotherapeutics Appoints Patrick Gallagher, MBA, MPH, as Chief Business Officer","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiWkFVX3lxTE1SaWdlVFotdFRUaktmOGxaOHF0VTN0blZ6SnBsakx6NXQ3dWhIRmpjM1laQWhXUERrd3p4a2ppbEE4T2dnWDgyZW5oUTdWX2dYdmdaOXFoa0RzZw?oc=5","date":"2021-02-05","type":"pipeline","source":"MarketBeat","summary":"Sensei Biotherapeutics (SNSE) Stock Price, News & Analysis - MarketBeat","headline":"Sensei Biotherapeutics (SNSE) Stock Price, News & Analysis","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiTkFVX3lxTFAySzNISUU5b0ZaSkQyWTJmV0dVaVFIclp3NFF5cE5BMk50TlYtdkFZQmIwVVpLbmhsbXBWY1lyQlZkajVQQUxnb2tyUjhRUQ?oc=5","date":"2021-02-04","type":"pipeline","source":"Stock Titan","summary":"Latest SNSE News - Sensei Biotherapeutics Reports Full Year 20... - Stock Titan","headline":"Latest SNSE News - Sensei Biotherapeutics Reports Full Year 20...","sentiment":"neutral"}],"patents":[{"drugName":"SB101","drugSlug":"sb101","patentNumber":"","type":"Patent Cliff","expiryDate":"2030-06-01","territory":"US","annualRevenue":0},{"drugName":"SB102","drugSlug":"sb102","patentNumber":"","type":"Patent Cliff","expiryDate":"2032-06-01","territory":"US","annualRevenue":0}],"drugCount":0,"phaseCounts":{},"enrichmentLevel":3,"visitCount":2,"keyCompetitors":["Bristol Myers Squibb","Merck & Co.","Roche Holding"],"therapeuticFocus":["Immuno-Oncology"],"financials":{"source":"sec_edgar+yahoo","revenue":null,"revenuePeriod":null,"revenueHistory":[],"grossProfit":null,"grossProfitHistory":[],"rdSpend":null,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-30157000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":null,"cashHistory":[],"totalAssets":45361000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":null}